{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,3]],"date-time":"2026-04-03T02:24:00Z","timestamp":1775183040597,"version":"3.50.1"},"reference-count":11,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","jns-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1016\/j.jns.2014.03.007","type":"journal-article","created":{"date-parts":[[2014,3,13]],"date-time":"2014-03-13T17:31:26Z","timestamp":1394731886000},"page":"109-111","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab"],"prefix":"10.1016","volume":"340","author":[{"given":"Reuben Mari","family":"Valenzuela","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Pula","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis","family":"Garwacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Cotter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge C.","family":"Kattah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.jns.2014.03.007_bb0005","first-page":"CD007621","article-title":"Natalizumab for relapsing remitting multiple sclerosis","author":"Pucci","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"10.1016\/j.jns.2014.03.007_bb0010","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis","volume":"354","author":"Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2014.03.007_bb0015","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ana.22163","article-title":"Natalizumab dose suspension: are we helping or hurting","volume":"68","author":"West","year":"2008","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2014.03.007_bb0020","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1212\/WNL.0b013e31821e7c8a","article-title":"Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis","volume":"76","author":"O'Connor","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.03.007_bb0025","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1001\/archneurol.2010.257","article-title":"Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy","volume":"68","author":"Miravalle","year":"2011","journal-title":"Arch Neurol"},{"issue":"7","key":"10.1016\/j.jns.2014.03.007_bb0030","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/NEN.0b013e31825caf2c","article-title":"Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab","volume":"71","author":"Kleinschmidt-Demasters","year":"2012","journal-title":"J Neuropathol Exp Neurol"},{"issue":"18","key":"10.1016\/j.jns.2014.03.007_bb0035","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1212\/WNL.0b013e318253d61e","article-title":"Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS","volume":"78","author":"Gheuens","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.03.007_bb0040","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1212\/WNL.0b013e318275979d","article-title":"Lethal multiple sclerosis relapse after natalizumab withdrawal","volume":"79","author":"Rigau","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.03.007_bb0045","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis","volume":"63","author":"Stuve","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2014.03.007_bb0050","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1086\/428618","article-title":"The role of immune reconstitution inflammatory syndrome in AIDS-related Cryptococcus neoformans disease in the era of highly active antiretroviral therapy","volume":"40","author":"Shelburne","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jns.2014.03.007_bb0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/01.aids.0000161769.06158.8a","article-title":"Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy","volume":"19","author":"Shelburne","year":"2005","journal-title":"AIDS"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14001506?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14001506?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T03:59:06Z","timestamp":1538798346000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X14001506"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":11,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0022510X14001506"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2014.03.007","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cryptococcal meningitis in a multiple sclerosis patient taking natalizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2014.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}